ATE106013T1 - Arzneimittelfreisetzungssystem aus glucan und adjuvant. - Google Patents

Arzneimittelfreisetzungssystem aus glucan und adjuvant.

Info

Publication number
ATE106013T1
ATE106013T1 AT90910219T AT90910219T ATE106013T1 AT E106013 T1 ATE106013 T1 AT E106013T1 AT 90910219 T AT90910219 T AT 90910219T AT 90910219 T AT90910219 T AT 90910219T AT E106013 T1 ATE106013 T1 AT E106013T1
Authority
AT
Austria
Prior art keywords
glucan
drug
pct
drug delivery
beta
Prior art date
Application number
AT90910219T
Other languages
English (en)
Inventor
Spiros Jamas
Gary R Ostroff
D Davidson Easson Jr
Original Assignee
Alpha Beta Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha Beta Technology filed Critical Alpha Beta Technology
Application granted granted Critical
Publication of ATE106013T1 publication Critical patent/ATE106013T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/817—Entrapped within the carrier, e.g. gel, hollow fibre

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT90910219T 1989-06-15 1990-06-14 Arzneimittelfreisetzungssystem aus glucan und adjuvant. ATE106013T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/366,490 US5032401A (en) 1989-06-15 1989-06-15 Glucan drug delivery system and adjuvant

Publications (1)

Publication Number Publication Date
ATE106013T1 true ATE106013T1 (de) 1994-06-15

Family

ID=23443232

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90910219T ATE106013T1 (de) 1989-06-15 1990-06-14 Arzneimittelfreisetzungssystem aus glucan und adjuvant.

Country Status (9)

Country Link
US (3) US5032401A (de)
EP (1) EP0476063B1 (de)
JP (1) JPH05503285A (de)
AT (1) ATE106013T1 (de)
AU (1) AU5933190A (de)
CA (1) CA2059275A1 (de)
DE (1) DE69009185T2 (de)
ES (1) ES2053198T3 (de)
WO (1) WO1990015596A1 (de)

Families Citing this family (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811542A (en) * 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
EP0490995A1 (de) * 1989-09-08 1992-06-24 Alpha Beta Technology Verfahren zur herstellung von wasserlöslichen glukanen
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
FR2655267B1 (fr) * 1989-12-04 1992-04-03 Roussel Uclaf Nouveau derive sulfate du galactanne extrait de klebsiella, procede de preparation, application a titre de medicaments et compositions pharmaceutiques le renfermant.
JPH0665649B2 (ja) * 1991-02-01 1994-08-24 台糖株式会社 甲殻類の生体防御能増強剤、感染症予防ワクチン及び飼料
FR2674755B1 (fr) * 1991-04-05 1995-02-03 Thorel Jean Noel Nouvelles compositions medicamenteuses immunostimulatrices.
JP3522772B2 (ja) * 1991-05-21 2004-04-26 台糖株式会社 ワクチンの免疫効果増強剤
IL104382A0 (en) * 1992-01-17 1993-05-13 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant
EP0640348A1 (de) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Adjuvansmischung auf Ölbasis und auf Wasserbasis
DE69426035T2 (de) * 1993-07-28 2001-05-17 Diatide, Inc. Radiomarkierte glukane
US5919466A (en) * 1993-10-01 1999-07-06 Gerbu Biotechnik Gmbh Method for improving the yield of immunoantibodies in the vaccination of animals and humans
AUPM572294A0 (en) * 1994-05-18 1994-06-09 Vaccine Technologies Pty. Ltd. Delivery vehicle for bioactive molecule
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
US5576015A (en) * 1995-03-02 1996-11-19 Donzis; Byron A. Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
AU6400796A (en) * 1995-06-26 1997-01-30 Research Triangle Pharmaceuticals Limited Novel adjuvant compositions and vaccine formulations comprising same
DE69637571D1 (de) * 1995-10-20 2008-08-07 Univ Nebraska Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
US20080286228A1 (en) * 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
US6084092A (en) * 1997-01-31 2000-07-04 The Collaborative Group, Ltd. β(1-3)-glucan diagnostic assays
US6110692A (en) 1996-05-01 2000-08-29 The Collaborative Group, Ltd. Receptor for underivatized aqueous soluble β(1-3)-glucan
JPH10139670A (ja) * 1996-11-11 1998-05-26 Terukuni Yakida インターロイキン１２誘導物質及び医薬組成物
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6413715B2 (en) 1997-01-31 2002-07-02 The Collaborative Group β(1-3)-glucan diagnostic assays
US5786343A (en) * 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
DE19737481A1 (de) * 1997-08-28 1999-03-04 Hoechst Ag Sphärische lineare Polysaccharide enthaltende Mikropartikel
IL135148A0 (en) * 1997-10-03 2001-05-20 Galenica Pharmaceuticals Inc A polysaccharide conjugate and pharmaceutical compositions containing the same
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
WO1999030691A2 (en) * 1997-12-18 1999-06-24 Ato B.V. Composition for the controlled release of active compounds
WO1999055715A2 (en) 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
EP1110091A1 (de) * 1998-09-04 2001-06-27 PowderJect Research Limited Immundiagnostika unter verwendung eines partikelaustragungsverfahrens
CA2344166C (en) * 1998-09-14 2008-11-18 Nabi Compositions of .beta.-glucans and specific igiv
US7030101B2 (en) 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
AU6261999A (en) * 1998-09-25 2000-04-17 Collaborative Group, Ltd., The Very high molecular weight beta-glucans
US6369216B1 (en) 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
US6541678B2 (en) * 1999-09-27 2003-04-01 Brennen Medical, Inc. Immunostimulating coating for surgical devices
US20020009463A1 (en) * 2000-02-23 2002-01-24 Jan Raa Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1357919B1 (de) * 2001-01-16 2017-04-05 Sloan-Kettering Institute For Cancer Research Glucan zur verbesserung der therapie
EP1372708B1 (de) 2001-02-13 2008-06-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY Impstoffe zur transkutanen immunisierung gegen reisediarrhö
WO2002087603A1 (en) * 2001-04-27 2002-11-07 Ajinomoto Co., Inc. Immunopotentiators
NO20014256D0 (no) 2001-09-03 2001-09-03 Bjoern Kristiansen Fremstilling av immunstimulerende forbindelse
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
ATE374796T1 (de) 2001-12-11 2007-10-15 Ceapro Inc Zusammensetzungen auf der basis von beta glukan aus getreiden, verfahren zur herstellung und verwendungen
WO2004012657A2 (en) * 2002-08-01 2004-02-12 Immusonic, Inc. Beta-glucan containing composites, methods for manufacturing and for using such composites
WO2004014320A2 (en) * 2002-08-13 2004-02-19 Biopolymer Engineering, Inc. Methods of using beta glucan as a radioprotective agent
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
CA2496596C (en) 2002-09-04 2016-06-28 Biopolymer Engineering, Inc. Cancer therapy using yeast insoluble .beta.-glucan particles and antibodies
US20050281875A1 (en) * 2003-12-17 2005-12-22 Sovereign Pharmaceuticals, Ltd. Promethazine containing dosage form
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20050232986A1 (en) * 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
US20060029664A1 (en) * 2004-08-04 2006-02-09 Sovereign Pharmaceuticals, Ltd. Dosage form containing carbetapentane and another drug
US20050232987A1 (en) * 2004-03-12 2005-10-20 Viswanathan Srinivasan Dosage form containing a morphine derivative and another drug
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
PL1711058T3 (pl) 2004-01-23 2022-02-07 Eden Research Plc Sposoby zabijania nicieni obejmujące aplikację składnika terpenowego
US20050208145A1 (en) * 2004-03-19 2005-09-22 Thava Vasanthan Grain fiber compositions and methods of use
US20050220846A1 (en) * 2004-04-05 2005-10-06 Puntenney Steven B Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function
DK1753529T3 (da) * 2004-05-20 2013-11-11 Eden Research Plc Komposition indeholdende en hul glucan-partikel eller en hul cellevægspartikel, der indkapsler en terpenkomponent, fremgangsmåder til fremstilling og anvendelse af disse
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US7514085B2 (en) 2004-07-16 2009-04-07 Medimush A/S Immune modulating compounds from fungi
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
US9592197B2 (en) * 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
CN101052383B (zh) * 2004-09-17 2013-01-30 马萨诸塞大学 用于溶酶体酶缺乏症的组合物和其用途
WO2006121803A1 (en) 2005-05-05 2006-11-16 Sensient Flavors Inc. Production of beta-glucans and mannans
WO2006133707A2 (en) 2005-06-15 2006-12-21 Medimush A/S Anti-cancer combination treatment and kit-of-part
EP1896601A1 (de) * 2005-06-15 2008-03-12 Medimush A/S Mittels einer basidiomyzeten-immersionszellkultur produzierte biologische wirkstoffe
JP5489462B2 (ja) * 2005-10-24 2014-05-14 ユニバーシティ オブ マサチューセッツ 骨病状の遺伝子治療のための組成物およびそれらの使用法
EP1954130B1 (de) 2005-11-30 2018-06-13 Eden Research Plc Verfahren umfassend terpenmischungen enthaltend thymol und citral
EP2982244B1 (de) 2005-11-30 2020-11-18 Eden Research Plc Thymolhaltige Insektizide Kapseln und Verfahren zu ihrer Herstellung und Verwendung
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
WO2007109564A2 (en) * 2006-03-17 2007-09-27 University Of Massachusetts Yeast cell particles as oral delivery vehicles for antigens
CN103833867B (zh) 2006-06-15 2017-07-04 生物高聚物工程公司Dba生物治疗公司 葡聚糖的制备
WO2008027580A2 (en) * 2006-09-01 2008-03-06 University Of Louisville PARTICULATE β-GLUCAN COMPOSITIONS FOR REGULATING DENDRITIC CELLS
WO2008027581A1 (en) * 2006-09-01 2008-03-06 University Of Louisville Mcrp antagonists and their uses
US20090022799A1 (en) * 2006-10-06 2009-01-22 Shikha Pramanik Barman Compositions that contain beta-glucan to be used for the prevention and treatment of disease and methods for their use
WO2008057501A2 (en) * 2006-11-06 2008-05-15 Whitehead Institute Immunomodulating compositions and methods of use thereof
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
EP2222283A2 (de) * 2007-10-29 2010-09-01 University of Massachusetts Zur freisetzung von nukleinsäuren (sirna) mit hefe-zellwandproteinen verkapselte mehrlagige nanopatikel
US9006219B2 (en) * 2008-03-12 2015-04-14 Nektar Therapeutics Oligomer-foscarnet conjugates
WO2009114151A1 (en) 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
EP2105145A1 (de) * 2008-03-27 2009-09-30 ETH Zürich Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
US20110059921A1 (en) * 2008-03-27 2011-03-10 Ektar Therapeutics Oligomer-Nitrogenous Base Conjugates
EP2265290B1 (de) * 2008-04-11 2014-06-04 Nektar Therapeutics Poly(alkylen oxid)-aryloxy-substituierte propanaminkonjugate
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
WO2010014258A2 (en) * 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
WO2010019233A1 (en) 2008-08-11 2010-02-18 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
WO2010021720A1 (en) 2008-08-19 2010-02-25 Nektar Therapeutics Conjugates of small-interfering nucleic acids
EP3208337A1 (de) 2008-09-02 2017-08-23 Alnylam Pharmaceuticals, Inc. Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6
US20110165113A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of v681-like peptides
WO2010033224A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of kiss1 peptides
WO2010033223A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
EP2334336A1 (de) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymerkonjugate von osteocalcin-peptiden
EP2340050A2 (de) * 2008-09-19 2011-07-06 Nektar Therapeutics Polymerkonjugate von aod-artigen peptiden
EP2344199A1 (de) * 2008-09-19 2011-07-20 Nektar Therapeutics Polymer-konjugate von thymosin-alpha1-peptiden
US20110165112A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of c-peptides
US20110206633A1 (en) * 2008-09-19 2011-08-25 Nektar Therapectics Polymer conjugates of cd-np peptides
EP2337585A1 (de) * 2008-09-19 2011-06-29 Nektar Therapeutics Polymerkonjugate von glp-2-artigen peptiden
US8680263B2 (en) * 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
WO2010099200A1 (en) 2009-02-24 2010-09-02 Nektar Therapeutics Oligomer-amino acid conjugates
WO2010099341A1 (en) 2009-02-26 2010-09-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mig-12 gene
US8816077B2 (en) 2009-04-17 2014-08-26 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
EP3504967A1 (de) 2009-05-05 2019-07-03 Arbutus Biopharma Corporation Verfahren zur abgabe von oligonukleotiden an immunzellen
JP5656980B2 (ja) 2009-05-13 2015-01-21 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー含有の置換芳香族トリアジン化合物
US8785661B2 (en) 2009-05-13 2014-07-22 Nektar Therapeutics Oligome-containing pyrrolidine compounds
US8916693B2 (en) 2009-09-17 2014-12-23 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
WO2011061144A2 (en) 2009-11-20 2011-05-26 Basf Se The present invention relates to the use of beta-(1, 3)- beta-(1, 4) glucan with an average molecular weight of from 5.000 to 150.000 da for the increase of synthesis of collagen
CZ302789B6 (cs) * 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
EP3766976A1 (de) 2009-12-18 2021-01-20 Arrowhead Pharmaceuticals, Inc. Organische zusammensetzungen zur behandlung von hsf1-bedingten erkrankungen
US9226970B2 (en) 2010-02-22 2016-01-05 Nektar Therapeutics Oligomer modified diaromatic substituted compounds
CN103200945B (zh) 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
KR101852210B1 (ko) 2010-03-24 2018-04-25 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
JP2013523162A (ja) 2010-04-06 2013-06-17 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｃｄ２７４／ｐｄ−ｌ１遺伝子の発現を阻害するための組成物および方法
KR20180033606A (ko) 2010-04-23 2018-04-03 애로우헤드 파마슈티컬스 인코포레이티드 베타-ＥＮａＣ-관련 질환을 치료하기 위한 유기 조성물
US20110293784A1 (en) 2010-05-28 2011-12-01 Anja Wittke Milk-based nutritional compositions
AU2011261434B2 (en) 2010-06-02 2015-11-26 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
US9242857B2 (en) 2010-08-14 2016-01-26 University Of Massachusetts Yeast cell wall particles for receptor-targeted nanoparticle delivery
EP2627639B1 (de) 2010-10-15 2021-12-22 Nektar Therapeutics N-optional substituierte aryl-2-oligomer-3-alkoxypropionamides
WO2012078967A2 (en) 2010-12-10 2012-06-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for increasing erythropoietin (epo) production
US9127275B2 (en) 2010-12-10 2015-09-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
WO2012082995A1 (en) 2010-12-15 2012-06-21 Nektar Therapeutics Oligomer-containing hydantoin compounds
WO2012083153A1 (en) 2010-12-16 2012-06-21 Nektar Therapeutics Oligomer-containing apremilast moiety compounds
US20130338216A1 (en) 2010-12-22 2013-12-19 Nektar Therapeutics Deuterated and/or fluorinated taxane derivatives
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US9827326B2 (en) 2010-12-23 2017-11-28 Nektar Therapeutics Polymer-sunitinib conjugates
US9943605B2 (en) 2010-12-23 2018-04-17 Nektar Therapeutics Polymer-semaxanib moiety conjugates
JP6009457B2 (ja) 2010-12-23 2016-10-19 ネクター セラピューティクス ポリマー−デスエチルスニチニブコンジュゲート
KR102365961B1 (ko) 2011-03-29 2022-02-23 알닐람 파마슈티칼스 인코포레이티드 Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
MX360782B (es) 2011-06-21 2018-11-16 Alnylam Pharmaceuticals Inc Composiciones de arni similares a angiopoyetina 3 (angptl3) y metodos para su uso.
WO2012177906A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
EP2723390B1 (de) 2011-06-23 2017-12-27 Alnylam Pharmaceuticals, Inc. Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
WO2013019857A2 (en) 2011-08-01 2013-02-07 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
EP3521432A1 (de) 2011-09-02 2019-08-07 Arrowhead Pharmaceuticals, Inc. Organische zusammensetzungen zur behandlung von hsf1-bedingten erkrankungen
WO2013105022A2 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
CN108355136B (zh) 2012-07-05 2021-12-07 纽崔玛氏科技有限责任公司 包含莱菔硫烷或莱菔硫烷前体和蕈类提取物或粉末的组合物
US9744193B2 (en) 2012-09-06 2017-08-29 Orbis Health Solutions Llc Tumor lysate loaded particles
US9375486B2 (en) 2012-09-17 2016-06-28 Nektar Therapeutics Oligomer-containing benzamide-based compounds
GB201220940D0 (en) 2012-11-21 2013-01-02 Eden Research Plc Method P
AU2013359392C1 (en) 2012-12-12 2016-12-08 Orbis Health Solutions, Llc Compositions and methods for tissue regeneration
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
SG10201912286TA (en) 2013-03-14 2020-02-27 Alnylam Pharmaceuticals Inc COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US10246708B2 (en) 2013-05-06 2019-04-02 Alnylam Pharmaceuticals, Inc. Dosages and methods for delivering lipid formulated nucleic acid molecules
EP3052626A1 (de) 2013-10-02 2016-08-10 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
US10119143B2 (en) 2013-10-04 2018-11-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
DK3056208T3 (en) * 2013-10-09 2021-11-15 Toray Industries Immunpotentiator
US20160278367A1 (en) 2013-11-21 2016-09-29 Eden Research Plc Pesticidal Composition
CN105960265A (zh) 2013-12-04 2016-09-21 阿克赛医药公司 利用经化学修饰的寡核苷酸处理伤口愈合的方法
WO2015092819A2 (en) 2013-12-21 2015-06-25 Nektar Therapeutics (India) Pvt. Ltd. Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
AU2015217301A1 (en) 2014-02-11 2016-08-25 Alnylam Pharmaceuticals, Inc. Ketohexokinase (KHK) iRNA compositions and methods of use thereof
AU2015217064B2 (en) 2014-02-12 2017-05-04 OmniGen Research, L.L.C. Composition and method for promoting reduction of heat stress in animals
SG11201607368XA (en) 2014-03-05 2016-10-28 Orbis Health Solutions Llc Vaccine delivery systems using yeast cell wall particles
WO2015168108A2 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic targeting mdm2 or mycn
US20170051290A1 (en) 2014-05-01 2017-02-23 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
TW201607559A (zh) 2014-05-12 2016-03-01 阿尼拉製藥公司 治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
CN106574268B (zh) 2014-05-22 2021-02-05 阿尔尼拉姆医药品有限公司 血管紧张素原（AGT）iRNA组合物及其使用方法
ES2877099T3 (es) 2014-07-10 2021-11-16 Hibercell Inc Beta-glucano en combinación con agentes anticáncer que afectan al microambiente tumoral
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
US20180010132A1 (en) 2014-09-11 2018-01-11 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
EP3207138B1 (de) 2014-10-17 2020-07-15 Alnylam Pharmaceuticals, Inc. Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
EP3904519A1 (de) 2014-10-30 2021-11-03 Genzyme Corporation Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
EP4046656A1 (de) 2014-11-06 2022-08-24 HiberCell, Inc. Die tumormikroumgebung beeinflussende verfahren und zusammensetzungen mit beta-glucan
US10479997B2 (en) 2014-12-01 2019-11-19 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
CA2969619A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
EP3234141A4 (de) 2014-12-18 2018-06-20 Alnylam Pharmaceuticals, Inc. Reversir-tm-verbindungen
CA2981715A1 (en) 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Chemically modified guide rnas for crispr/cas-mediated gene regulation
EP3302525A2 (de) 2015-06-05 2018-04-11 Novartis AG Verfahren und zusammensetzungen zur diagnose, behandlung und überwachung der behandlung von shank3-mangelbedingten erkrankungen
EP3307316A1 (de) 2015-06-12 2018-04-18 Alnylam Pharmaceuticals, Inc. Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
WO2016205323A1 (en) 2015-06-18 2016-12-22 Alnylam Pharmaceuticals, Inc. Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en) 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
KR20180026739A (ko) 2015-07-06 2018-03-13 알엑스아이 파마슈티칼스 코포레이션 슈퍼옥시드 디스뮤타제 1 (sod1)을 표적화하는 핵산 분자
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
WO2017011286A1 (en) 2015-07-10 2017-01-19 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
CN107922949A (zh) 2015-08-31 2018-04-17 安捷伦科技有限公司 用于通过同源重组的基于crispr/cas的基因组编辑的化合物和方法
EP4393495A3 (de) 2015-09-02 2024-09-25 Alnylam Pharmaceuticals, Inc. Irna-zusammensetzungen mit programmiertem zelltod 1-ligand 1 (pd-l1) und verfahren zur verwendung davon
CA2997553A1 (en) 2015-09-09 2017-03-16 Omnigen Research, Llc A particulate composition comprising silica, mineral clay, glucan and mannans for aquaculture
JP2018531037A (ja) 2015-10-19 2018-10-25 アールエックスアイ ファーマシューティカルズ コーポレーション 長い非コードｒｎａを標的とする減少したサイズの自己送達型核酸化合物
IL259795B2 (en) 2015-12-07 2024-04-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
EP3469083A1 (de) 2016-06-10 2019-04-17 Alnylam Pharmaceuticals, Inc. Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
EP3484450A4 (de) * 2016-07-18 2020-04-01 Tissuegen, Inc. Verfahren und zusammensetzungen zur aufrechterhaltung der konformation und strukturellen integrität von biomolekülen
EP3535396A1 (de) 2016-11-01 2019-09-11 Novartis AG Verfahren und zusammensetzungen zur verbesserung der genbearbeitung
BR112019014287B1 (pt) * 2017-01-10 2022-11-16 Unilever Ip Holdings B.V. Microcápsula direcionada a biofilme, método de fornecimento de um material funcional não volátil a um biofilme e uso de polímero polissacarídeo não iônico
AU2018207283C1 (en) 2017-01-10 2024-05-02 Nektar Therapeutics Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods
US11815435B2 (en) 2017-02-24 2023-11-14 Hibercell, Inc. Beta glucan immunopharmacodynamics
WO2018195355A1 (en) 2017-04-19 2018-10-25 Rxi Pharmaceuticals Corporation Topical delivery of nucleic acid compounds
MA48862A (fr) 2017-05-02 2020-04-01 Nektar Therapeutics Méthode de traitement de tumeur immunothérapeutique
CN111093771A (zh) 2017-07-10 2020-05-01 建新公司 在患有血友病的受试者中治疗出血事件的方法和组合物
EP3652317A1 (de) 2017-07-13 2020-05-20 Alnylam Pharmaceuticals, Inc. Lactatdehydrogenase-a (ldha)-irna-zusammensetzungen und verfahren zu ihrer verwendung
EP3655004A2 (de) 2017-07-21 2020-05-27 Novartis AG Zusammensetzungen und verfahren zur behandlung von krebs
EP3668548A2 (de) 2017-08-17 2020-06-24 Nektar Therapeutics Immuntherapeutisches tumorbehandlungsverfahren
MX2020004507A (es) 2017-11-09 2020-08-13 Alnylam Pharmaceuticals Inc Ensayos y métodos para determinar la expresión del gen de quimiotaxina 2 derivada de leucocitos (lect2).
WO2019094962A2 (en) * 2017-11-13 2019-05-16 The Regents Of The University Of California Antimicrobial particles and sanitization methods
US10835581B2 (en) 2017-11-28 2020-11-17 University of Pittsburgh—of the Commonwealth System of Higher Education Method of treating insulin resistance
US11179412B2 (en) 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
GB201800417D0 (en) * 2018-01-11 2018-02-28 Whelan Adam Owen Immunogenic agent and associated compositions, uses and methods
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
WO2019165212A1 (en) 2018-02-22 2019-08-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education TARGETING CANCER-ASSOCIATED LONG NON-CODING RNAs
CN110237249A (zh) * 2018-03-09 2019-09-17 南开大学 特异靶向树突状细胞的新型铝佐剂及在疫苗制备上的应用
US20210023017A1 (en) * 2018-03-16 2021-01-28 University Of Massachusetts Yeast cell wall particle encapsulation of biodegradable pro-payloads
WO2019213276A1 (en) 2018-05-02 2019-11-07 Novartis Ag Regulators of human pluripotent stem cells and uses thereof
EP3837367A1 (de) 2018-08-16 2021-06-23 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
CN118667811A (zh) 2018-09-18 2024-09-20 阿尔尼拉姆医药品有限公司 己酮糖激酶(KHK)iRNA组合物及其使用方法
US10913951B2 (en) 2018-10-31 2021-02-09 University of Pittsburgh—of the Commonwealth System of Higher Education Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
PL4285929T3 (pl) 2018-12-20 2026-03-23 Humabs Biomed Sa Terapia skojarzona hbv
NO346800B1 (en) 2019-06-28 2023-01-16 Ederagen As Deconstructed soil composition
CN114616331B (zh) 2019-09-03 2024-10-22 阿尔尼拉姆医药品有限公司 抑制lect2基因表达的组合物和方法
WO2021067747A1 (en) 2019-10-04 2021-04-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing ugt1a1 gene expression
US20230040920A1 (en) 2019-11-01 2023-02-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
US20230002766A1 (en) 2019-11-08 2023-01-05 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
MX2022009763A (es) 2020-02-10 2022-09-09 Alnylam Pharmaceuticals Inc Composiciones y metodos para silenciar la expresion del factor de crecimiento endotelial vascular a (vegf-a).
US20230092615A1 (en) 2020-02-21 2023-03-23 Mitotherapeutix Llc Compositions and methods for inhibiting expressing of methylation-controlled j-protein (mcj)
US20230190785A1 (en) 2020-03-30 2023-06-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajc15 gene expression
MX2022012493A (es) 2020-04-06 2022-10-27 Alnylam Pharmaceuticals Inc Composiciones y metodos para el silenciamiento de la expresion de miocilina (myoc).
AU2021251754A1 (en) 2020-04-07 2022-11-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing SCN9A expression
WO2021237097A1 (en) 2020-05-21 2021-11-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
WO2021252649A2 (en) 2020-06-09 2021-12-16 Alnylam Pharmaceuticals, Inc. Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
US20230242621A1 (en) 2020-06-24 2023-08-03 Vir Biotechnology, Inc. Engineered hepatitis b virus neutralizing antibodies and uses thereof
JPWO2022045371A1 (de) * 2020-08-31 2022-03-03
AU2022339821A1 (en) 2021-08-31 2024-03-07 Alnylam Pharmaceuticals, Inc. Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof
CA3230927A1 (en) 2021-09-10 2023-03-16 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
CR20240196A (es) 2021-11-16 2024-07-08 Shanghai Argo Biopharmaceutical Co Ltd Composiciones y métodos para inhibir la expresión de la proteína angiotensinógeno (agt)
AU2022395876A1 (en) 2021-11-29 2024-05-09 Shanghai Argo Biopharmaceutical Co., Ltd. Composition and method for inhibiting expression of hepatitis b virus (hbv) protein
TW202345865A (zh) 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
CN115317601B (zh) * 2022-04-13 2026-02-27 暨南大学 一种新冠疫苗载体及其应用
EP4569113A1 (de) 2022-09-15 2025-06-18 Regeneron Pharmaceuticals, Inc. 17b-hydroxysteroiddehydrogenase-typ-13 (hsd17b13)-irna-zusammensetzungen und verfahren zu ihrer verwendung
TW202449152A (zh) 2023-02-09 2024-12-16 美商艾拉倫製藥股份有限公司 Ｒｅｖｅｒｓｉｒ分子及其使用方法
WO2025128622A1 (en) 2023-12-12 2025-06-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating transthyretin (ttr)- associated diseases
WO2025128632A1 (en) 2023-12-12 2025-06-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating ketohexokinase (khk)-associated diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2447193A1 (fr) * 1979-01-25 1980-08-22 Unicler Utilisation de pichia ou d'extraits de pichia, comme medicament.
JPS59148726A (ja) * 1983-02-09 1984-08-25 Rooto Seiyaku Kk 徐放性製剤用賦形剤
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US4857505A (en) * 1987-03-09 1989-08-15 American Cyanamid Company Sustained release compositions for parenteral administration and their use

Also Published As

Publication number Publication date
EP0476063A1 (de) 1992-03-25
DE69009185D1 (de) 1994-06-30
US5607677A (en) 1997-03-04
EP0476063B1 (de) 1994-05-25
JPH05503285A (ja) 1993-06-03
US5032401A (en) 1991-07-16
CA2059275A1 (en) 1990-12-16
US5741495A (en) 1998-04-21
ES2053198T3 (es) 1994-07-16
WO1990015596A1 (en) 1990-12-27
AU5933190A (en) 1991-01-08
DE69009185T2 (de) 1994-10-27

Similar Documents

Publication Publication Date Title
ATE106013T1 (de) Arzneimittelfreisetzungssystem aus glucan und adjuvant.
ATE157257T1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
TR199802305T2 (xx) Yanaktan uygulama y�ntemi.
AR042262A2 (es) Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
ES2172239T3 (es) Sistema osmotico de liberacion de farmacos.
DK0663815T3 (da) Inhalationspulvere og fremgangsmåde til fremstilling heraf
ATE159425T1 (de) Arzneimittelzusammensetzung für verabreichung von nikotin durch die nase
JPS57212114A (en) Capsule containing allergen activator and preparation therefor
GR3021438T3 (en) Application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes.
NO20000378L (no) Anvendelse av MHC klasse II ligander som adjuvantia for vaksinasjon og LAG-3 i kreftbehandling
EP0652770A4 (de) Orale gabe von antigenen.
RU94045825A (ru) Применение материала, полученного из mycobacterium vaccae для производства терапевтического средства для лечения психических заболеваний, способ лечения психических заболеваний, продукт, содержащий антигенный и/или иммунорегуляторный материал, фармацевтическое средство
ATE179333T1 (de) Immunotherapeutische zubereitung
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
DE69812100D1 (de) Adenosin enthaltendes arzneimittel
EP0368992A4 (en) Actions of hormones
RU94002476A (ru) Лекарственное средство
EP0282343A3 (de) Verfahren zur Stimulierung der Immunreponsibilität zu bestimmten Antigenen
ES2182983T3 (es) Formulaciones para la liberacion de peptidos.
GEP20012571B (en) New Application of Lyzocyme Dimer
IL105498A0 (en) Pharmaceutical composition containing ribonucleotide polymerase
DE69429521D1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
MY110074A (en) Pharmacuetical formulation.
EP0480391A3 (en) Emulsion-free emulsion polymers, their production and their use in sustained-release pharmaceutical compositions
MX9302986A (es) Medicamento que contiene metrifonato y procedimiento para su preparacion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties